Status:
COMPLETED
Eplerenone and Extracellular Adenosine Formation
Lead Sponsor:
Radboud University Medical Center
Conditions:
Pharmacodynamics
Eligibility:
MALE
18-40 years
Phase:
PHASE4
Brief Summary
Various studies have reported cardioprotective effects of mineralocorticoid receptor (MR) antagonists in the setting of an acute myocardial infarction. In a recent animal study, the protective effect ...
Eligibility Criteria
Inclusion
- Male sex
- Age 18-40 years
- Healthy
- Written informed consent
Exclusion
- Smoking
- Hypertension (Blood pressure \>140 mmHg and/or \>90 mmHg - SBP/DBP-)
- Hypotension (Blood pressure \<100 mmHg and/or \<60 mmHg -SBP/DBP-)
- Diabetes Mellitus (fasting glucose \> 6.9 mmol/L or random \> 11.0 mmol/L in venous plasma)
- History of any cardiovascular disease
- Angina pectoris
- History of chronic obstructive pulmonary disease (COPD) or asthma
- Alcohol and/or drug abuse
- Concomitant use of medication
- Renal dysfunction (MDRD \< 60 ml/min/1.73 m2)
- Liver enzyme abnormalities (ALAT \> twice upper limit of normality)
- Serum potassium ≥ 4.8 mmol/L
- Fasting total cholesterol \> 6.0 mmol/L
- Second/third degree AV-block on electrocardiography
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01837108
Start Date
April 1 2013
End Date
January 1 2014
Last Update
January 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Medical Centre
Nijmegen, Gelderland, Netherlands, 6525EZ